320 related articles for article (PubMed ID: 36085041)
1. From Bowen disease to cutaneous squamous cell carcinoma: eight markers were verified from transcriptomic and proteomic analyses.
Biao T; Cai-Feng H; Xiao-Hong L; Xiao-Li C; Wen-Bei L; Jun W; Chao C; Tao Y
J Transl Med; 2022 Sep; 20(1):416. PubMed ID: 36085041
[TBL] [Abstract][Full Text] [Related]
2. [Yes-associated protein (YAP) promotes invasion and migration of cutaneous squamous cell carcinoma cells by activating the PI3K/AKT pathway].
Li Z; Yang F; Jin X; Wang X; Chen T; Quan C
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Mar; 40(3):244-251. PubMed ID: 38512035
[TBL] [Abstract][Full Text] [Related]
3. lncRNA EZR‑AS1 knockdown represses proliferation, migration and invasion of cSCC via the PI3K/AKT signaling pathway.
Lu D; Sun L; Li Z; Mu Z
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236153
[TBL] [Abstract][Full Text] [Related]
4. Data Independent Acquisition Proteomic Analysis Can Discriminate between Actinic Keratosis, Bowen's Disease, and Cutaneous Squamous Cell Carcinoma.
Azimi A; Yang P; Ali M; Howard V; Mann GJ; Kaufman KL; Fernandez-Penas P
J Invest Dermatol; 2020 Jan; 140(1):212-222.e11. PubMed ID: 31254517
[TBL] [Abstract][Full Text] [Related]
5. Differential proteomic analysis of actinic keratosis, Bowen's disease and cutaneous squamous cell carcinoma by label-free LC-MS/MS.
Azimi A; Kaufman KL; Ali M; Arthur J; Kossard S; Fernandez-Penas P
J Dermatol Sci; 2018 Jul; 91(1):69-78. PubMed ID: 29665991
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNA LINC00520 prevents the progression of cutaneous squamous cell carcinoma through the inactivation of the PI3K/Akt signaling pathway by downregulating EGFR.
Mei XL; Zhong S
Chin Med J (Engl); 2019 Feb; 132(4):454-465. PubMed ID: 30707166
[TBL] [Abstract][Full Text] [Related]
7. Non-invasive diagnosis of early cutaneous squamous cell carcinoma.
Azimi A; Jabbour S; Patrick E; Fernandez-Penas P
Exp Dermatol; 2023 Nov; 32(11):1946-1959. PubMed ID: 37688398
[TBL] [Abstract][Full Text] [Related]
8. Potential role of the OVOL1-OVOL2 axis and c-Myc in the progression of cutaneous squamous cell carcinoma.
Ito T; Tsuji G; Ohno F; Nakahara T; Uchi H; Furue M
Mod Pathol; 2017 Jul; 30(7):919-927. PubMed ID: 28339425
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of kynureninase restrains cutaneous squamous cell carcinoma proliferation and represses the PI3K/AKT pathway.
Ci C; Wu C; Lyu D; Chang X; He C; Liu W; Chen L; Ding W
Clin Exp Dermatol; 2020 Mar; 45(2):194-201. PubMed ID: 31419330
[TBL] [Abstract][Full Text] [Related]
10. Telomeres and Telomerase in Cutaneous Squamous Cell Carcinoma.
Ventura A; Pellegrini C; Cardelli L; Rocco T; Ciciarelli V; Peris K; Fargnoli MC
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30884806
[TBL] [Abstract][Full Text] [Related]
11. Integrated tissue proteome and metabolome reveal key elements and regulatory pathways in cutaneous squamous cell carcinoma.
Chen W; Rao J; Liu Z; You X; Yuan F; Le F; Tang M; Zhou M; Xie T
J Proteomics; 2021 Sep; 247():104320. PubMed ID: 34237460
[TBL] [Abstract][Full Text] [Related]
12. Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma.
Riihilä PM; Nissinen LM; Ala-Aho R; Kallajoki M; Grénman R; Meri S; Peltonen S; Peltonen J; Kähäri VM
J Invest Dermatol; 2014 Feb; 134(2):498-506. PubMed ID: 23938460
[TBL] [Abstract][Full Text] [Related]
13. Expression and significance of mammalian target of rapamycin in cutaneous squamous cell carcinoma and precancerous lesions.
Xu G; Fang J; Xu J; Shen Z; Huang C; Jiang Y
Bioengineered; 2021 Dec; 12(2):9930-9938. PubMed ID: 34874800
[TBL] [Abstract][Full Text] [Related]
14. Plexin-B1 and semaphorin 4D cooperate to promote cutaneous squamous cell carcinoma cell proliferation, migration and invasion.
Cao J; Zhang C; Chen T; Tian R; Sun S; Yu X; Xiao C; Wang G; Liu Y; Fu M; Li W
J Dermatol Sci; 2015 Aug; 79(2):127-36. PubMed ID: 26051877
[TBL] [Abstract][Full Text] [Related]
15. Durable Clearance Rate of Photodynamic Therapy for Bowen Disease and Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.
Yongpisarn T; Rigo R; Minkis K
Dermatol Surg; 2022 Apr; 48(4):395-400. PubMed ID: 35143444
[TBL] [Abstract][Full Text] [Related]
16. Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma.
Gambichler T; Gnielka M; Rüddel I; Stockfleth E; Stücker M; Schmitz L
Cancer Immunol Immunother; 2017 Sep; 66(9):1199-1204. PubMed ID: 28501937
[TBL] [Abstract][Full Text] [Related]
17. Identification of potential gene drivers of cutaneous squamous cell carcinoma: Analysis of microarray data.
Zheng Y; Chi S; Li C
Medicine (Baltimore); 2020 Sep; 99(39):e22257. PubMed ID: 32991423
[TBL] [Abstract][Full Text] [Related]
18. Artesunate restrains the malignant progression of human cutaneous squamous cell carcinoma cells via the suppression of the PI3K/AKT pathway.
Huang X; Zhang S; Wang W
Tissue Cell; 2022 Jun; 76():101789. PubMed ID: 35338984
[TBL] [Abstract][Full Text] [Related]
19. Transglutaminase 3 regulates cutaneous squamous carcinoma differentiation and inhibits progression via PI3K-AKT signaling pathway-mediated Keratin 14 degradation.
Zhou K; Wu C; Cheng W; Zhang B; Wei R; Cheng D; Li Y; Cao Y; Zhang W; Yao Z; Zhang X
Cell Death Dis; 2024 Apr; 15(4):252. PubMed ID: 38589352
[TBL] [Abstract][Full Text] [Related]
20. High-frequency ultrasound in the diagnosis of the spectrum of cutaneous squamous cell carcinoma: Noninvasively distinguishing actinic keratosis, Bowen's Disease, and invasive squamous cell carcinoma.
Zhu AQ; Wang LF; Li XL; Wang Q; Li MX; Ma YY; Xiang LH; Guo LH; Xu HX
Skin Res Technol; 2021 Sep; 27(5):831-840. PubMed ID: 33751714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
